Cargando…
Mutational interactions define novel cancer subgroups
Large-scale genomic data highlight the complexity and diversity of the molecular changes that drive cancer progression. Statistical analysis of cancer data from different tissues can guide drug repositioning as well as the design of targeted treatments. Here, we develop an improved Bayesian network...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195543/ https://www.ncbi.nlm.nih.gov/pubmed/30341300 http://dx.doi.org/10.1038/s41467-018-06867-x |
_version_ | 1783364406381379584 |
---|---|
author | Kuipers, Jack Thurnherr, Thomas Moffa, Giusi Suter, Polina Behr, Jonas Goosen, Ryan Christofori, Gerhard Beerenwinkel, Niko |
author_facet | Kuipers, Jack Thurnherr, Thomas Moffa, Giusi Suter, Polina Behr, Jonas Goosen, Ryan Christofori, Gerhard Beerenwinkel, Niko |
author_sort | Kuipers, Jack |
collection | PubMed |
description | Large-scale genomic data highlight the complexity and diversity of the molecular changes that drive cancer progression. Statistical analysis of cancer data from different tissues can guide drug repositioning as well as the design of targeted treatments. Here, we develop an improved Bayesian network model for tumour mutational profiles and apply it to 8198 patient samples across 22 cancer types from TCGA. For each cancer type, we identify the interactions between mutated genes, capturing signatures beyond mere mutational frequencies. When comparing mutation networks, we find genes which interact both within and across cancer types. To detach cancer classification from the tissue type we perform de novo clustering of the pancancer mutational profiles based on the Bayesian network models. We find 22 novel clusters which significantly improve survival prediction beyond clinical information. The models highlight key gene interactions for each cluster potentially allowing genomic stratification for clinical trials and identifying drug targets. |
format | Online Article Text |
id | pubmed-6195543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-61955432018-10-22 Mutational interactions define novel cancer subgroups Kuipers, Jack Thurnherr, Thomas Moffa, Giusi Suter, Polina Behr, Jonas Goosen, Ryan Christofori, Gerhard Beerenwinkel, Niko Nat Commun Article Large-scale genomic data highlight the complexity and diversity of the molecular changes that drive cancer progression. Statistical analysis of cancer data from different tissues can guide drug repositioning as well as the design of targeted treatments. Here, we develop an improved Bayesian network model for tumour mutational profiles and apply it to 8198 patient samples across 22 cancer types from TCGA. For each cancer type, we identify the interactions between mutated genes, capturing signatures beyond mere mutational frequencies. When comparing mutation networks, we find genes which interact both within and across cancer types. To detach cancer classification from the tissue type we perform de novo clustering of the pancancer mutational profiles based on the Bayesian network models. We find 22 novel clusters which significantly improve survival prediction beyond clinical information. The models highlight key gene interactions for each cluster potentially allowing genomic stratification for clinical trials and identifying drug targets. Nature Publishing Group UK 2018-10-19 /pmc/articles/PMC6195543/ /pubmed/30341300 http://dx.doi.org/10.1038/s41467-018-06867-x Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Kuipers, Jack Thurnherr, Thomas Moffa, Giusi Suter, Polina Behr, Jonas Goosen, Ryan Christofori, Gerhard Beerenwinkel, Niko Mutational interactions define novel cancer subgroups |
title | Mutational interactions define novel cancer subgroups |
title_full | Mutational interactions define novel cancer subgroups |
title_fullStr | Mutational interactions define novel cancer subgroups |
title_full_unstemmed | Mutational interactions define novel cancer subgroups |
title_short | Mutational interactions define novel cancer subgroups |
title_sort | mutational interactions define novel cancer subgroups |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195543/ https://www.ncbi.nlm.nih.gov/pubmed/30341300 http://dx.doi.org/10.1038/s41467-018-06867-x |
work_keys_str_mv | AT kuipersjack mutationalinteractionsdefinenovelcancersubgroups AT thurnherrthomas mutationalinteractionsdefinenovelcancersubgroups AT moffagiusi mutationalinteractionsdefinenovelcancersubgroups AT suterpolina mutationalinteractionsdefinenovelcancersubgroups AT behrjonas mutationalinteractionsdefinenovelcancersubgroups AT goosenryan mutationalinteractionsdefinenovelcancersubgroups AT christoforigerhard mutationalinteractionsdefinenovelcancersubgroups AT beerenwinkelniko mutationalinteractionsdefinenovelcancersubgroups |